Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Make a nice bounce for sure..Tnx
BM #9..Checking in
KR..We need another bottom runner
CC..Looks good for tomorrow.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=79093312
Sorry bud, nothing cheap 4-U..Get um now
WGAS +121% Gapper Tomorrow
$WGAS 1Mil bid @ .015 +121%
$WGAS - .0135 x .0140 +98% Penny Stock Spy
$WGAS - Huge blocks going thru +71%
$WGAS - Solid .009 Break Ticker +65%
$WGAS .011 x .012 +58% News-Chart >
Worthington Energy Brings I-1 Well On Line
http://ih.advfn.com/p.php?pid=nmona&article=53997213
WGAS .011 x .012 +55%
$WGAS...01 Break - News-Chart>
Worthington Energy Brings I-1 Well On Line
http://ih.advfn.com/p.php?pid=nmona&article=53997213
WGAS News - Brings I-1 Well On Line
http://ih.advfn.com/p.php?pid=nmona&article=53997213
To funny video
$PRTN.. After Hrs. News.
3 days in a row. Old school
http://ih.advfn.com/p.php?pid=nmona&article=53988463
Got the .41 sellers
and the .42 block out. Hit a nHOD and we run.
Nice Chart & News today
tickers breaking .01's w/news can be good runners.. MSLP
News was right on time. Chart says its ready.
Expect to see a nice move here..MSLP
Didn't know if you guy's
had seen the press. Hope this turns into something for PRTN and APS. All good so far.
PRTN News Out
BEVERLY HILLS, Calif., Aug. 28, 2012 /PRNewswire via COMTEX/ -- Eaton
Scientific Systems, Ltd. ("Eaton Scientific" or the "Company"), a wholly owned
subsidiary of Pristine Solutions, Inc. (OTCQB: PRTN) is pleased to announce
select details of its planned multi-phase multi-location clinic trials for FDA
approval of its novel drug indication Tropine 3, containing currently FDA
approved Homatropine, in oral an suspension.
"We are currently finalizing preparations for what we believe will be the
landmark clinical studies of our novel drug indication Tropine 3 for treatment
and relief of the symptoms of hot flashes in menopausal women - one of the top
concerns of women's healthcare today," stated Michael Borkowski, CEO and
President of Eaton Scientific. "The Company continues to build an outstanding
team of very highly accredited medical professionals to plan, manage, and
conduct every step of the clinic trials which were specifically designed to
test, prove, and ultimately promote the short-term efficacy and safety Tropine
3. We anticipate that final Phase 1-2 protocol preparations and patient
enrollment start dates will be confirmed shortly."
Eaton intends to conduct multiple clinical trials in Phase 1-2 & Phase 3 of
Tropine 3. The first trial is planned to be an FDA protocol approved "Phase 1-2,
Prospective, Randomized, Double Blind, Placebo-Controlled, Dose Escalation,
Parallel-Group Study to Test the Efficacy and Safety of Homatropine
Methylbromide Oral Suspension on Selected Climacteric Symptoms and Quality of
Life in Menopausal Women Not Receiving Hormonal Replacement Therapy ("HRT")".
The drug, homatropine, is an anticholinergic medication that is an antagonist at
muscarinic acetylcholine receptors and thus the parasympathetic nervous system.
It is used in eye drops as a cycloplegic, and as a mydriatic in order to dilate
the pupil. Homatropine is also given as an atropine substitute given to reverse
the muscarinic and CNS effects associated with indirect cholinomimetic
administration. Homatropine has been prescribed continuously and safely in the
United States for over 40 years.
The Company anticipates conducting the clinic trials at multiple sites across
the United States and plans to publish the results in medical journals and
women's health publications. The Company intends to begin marketing Tropine 3 to
pharmaceutical companies for potential acquisition following completion of the
first Phase 1-2 clinic trial.
About Pristine Solutions, Inc.
Pristine Solutions, Inc., through its wholly-owned subsidiary company, Eaton
Scientific Systems, Ltd., holds the intellectual property and global marketing
rights to Tropine 3, a patent pending novel indication of an existing FDA
approved drug for the non-hormonal treatment of hot flashes in pre-menopausal,
pari-menopausal, and post-menopausal women.
Forward-Looking Statements/Disclaimer
Information in this document constitute forward-looking statements or statements
which may be deemed or construed to be forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. The words
"forecast", "anticipate", "estimate", "project", "intend", "expect", "should",
"believe", and similar expressions are intended to identify forward-looking
statements. These forward-looking statements involve, and are subject to known
and unknown risks, uncertainties and other factors which could cause Pristine
Solutions' actual results, performance (financial or operating) or achievements
to differ from the future results, performance (financial or operating) or
achievements expressed or implied by such forward-looking statements. The risks,
uncertainties and other factors are more fully discussed in Pristine Solutions'
filings with the U.S. Securities and Exchange Commission. All forward-looking
statements attributable to Pristine Solutions herein are expressly qualified in
their entirety by the above-mentioned cautionary statement. Pristine Solutions
disclaims any obligation to update forward-looking statements contained in this
estimate, except as may be required by law.
SOURCE Eaton Scientific Systems, Ltd.
www.prnewswire.com
Hold'em..You don't
have much choice.
Getting closer to 4
HAL*? Been reading to many PM's.
Moving Up
SBRH .Setting Up +23% NHOD
BION .077 x .0869 +24%
SBRH .0014 x .0015 +15%
SAPX Solid
APS E-Mail
Hi Everyone,
As announced yesterday our new pick is $PRTN and it is already doing phenomenal for our members. We do know that many of you are still on vacation (including most of wallstreet), and are not trading until the beginning of September.
That's in fact where the fancy term September Rally comes from. September has historically been huge for the markets, and we think that PRTN will also benefit from a huge uptrend throughout the month, and that uptrend begins now.
Premium Members had the opportunity to come in at the market open yesterday and have already secured gains of about 50% (so for next time if you would like the same opportunity head over to PremiumStockReport dot com and sign up now).
That being said PRTN still offers ridiculous upside potential for our members as it is still trading at just 35 cents and none of our biotech picks has ever produced less than 1,000%
In fact our most recent pick in the pharmaceuticals industry soared from an initial price of about 30 cents to well over $2 within a 8-week time period.
PRTN confirmed the acquisition of Eaton Scientific Systems, Ltd., a biomedical product development company focused on women's health solutions.
Eaton Scientific has identified, developed, and filed a patent for a novel indication of an existing FDA approved drug, homatropine, for the non-hormonal treatment of hot flashes in pre-menopausal, pari-menopausal, and post-menopausal women.
The drug indication, that Eaton Scientific named Tropine 3, is currently being prescribed and compounded by doctors in the Los Angeles, California specifically for their patients who have hot flash symptoms and do not want to take hormonal treatment. The drug, homatropine, is an anticholinergic medication that is an antagonist at muscarinic acetylcholine receptors and thus the parasympathetic nervous system. It is used in eye drops as a cycloplegic, and as a mydriatic in order to dilate the pupil. Homatropine is also given as an atropine substitute given to reverse the muscarinic and CNS effects associated with indirect cholinomimetic administration.
Tropine 3 has been shown in individual cases to reduce the symptoms of hot flashes in terms of intensity, duration, and number of occurrences without the use of dangerous hormones which," said Michael Borkowski, CEO and President of Eaton Scientific Systems, Ltd. "We look forward to building market awareness and acceptance of Tropine 3 throughout the women's health care sector in hopes of improving the lives of the over 50 million women in America that would benefit from this proven safe and effective treatment for hot flashes."
The Company is currently assembling a senior management team and group of scientific advisors to assist in the ongoing development and clinical testing of Tropine 3. Clinical trials currently being contemplated will be performed to strict FDA standards to provide support to claims made in Eaton Scientific's patent filed under USPTO #60/719,756. Additional information regarding the near-term scheduling and commencement of planned Tropine 3 clinical trials will be made available in subsequent public statements.
You can visit the company's site at EatonScientific dot com
We plan on covering PRTN for a while as we follow the company's progress on FDA clinical trials for Tropine 3.
Pharmaceutical stocks always soar after the FDA approves a drug in the pipeline and PRTN could do the same should clinical trials of Tropine 3 be successful and the FDA approves it.
In fact we saw a "pennystock" (on pinksheet) soar more than 2,000% in a single day after the FDA approved one of its drugs. The company was TTNP it went from 3 cents to more than $2 about 36 months ago. It soared in less than 30 days. and is still sitting at around $1 even today!
That's the type of enormous positive effect an FDA approval can have on a stock as it creates millionaires virtually overnight.
Watch PRTN very closely over the next few weeks as it is officially our most anticipated alert of the (end of) summer!
Happy Trading!
Your AwesomePennyStocks Editor.